PF-05230905
/ Sanofi
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
November 04, 2011
Ablynx regains rights from Pfizer to Nanobodies targeting TNF-alpha
(Ablynx)
- Ablynx announced that it has regained worldwide rights from Pfizer to develop and commercialize Nanobodies targeting TNF-alpha; These rights include the product ATN-103 & PF-05230905; Ablynx will undertake a detailed review of the programs before deciding how to proceed
Collaboration termination • Inflammatory Bowel Disease • Psoriasis • Rheumatoid Arthritis
April 05, 2012
Annual Report '11
(Ablynx)
- ATN -192 / Ablynx; Anticipated data for P1 trial for RA in H1 2012
Anticipated P1 data • Rheumatoid Arthritis
1 to 2
Of
2
Go to page
1